甲状腺癌PBL课件.pptVIP

Sixteen trial patients were enrolled; 15 were treated,11 of 15 had progressed through prior systemic therapy. Four patients required one to two dose reductions; severe toxicities (grades 3) were hypertension (13%) and pharyngolaryngeal pain (13%). Treatment was discontinued because of : disease progression (12 patients), death due to a possibly treatment-related tumor hemorrhage (one patient), and intolerability (radiation recall tracheitis and uncontrolled hypertension, one patient each). Median time to progression was 62 d; median survival time was 111 d. Findings 靶向药物-舒尼替尼 Phase 2 clini